AGARWALEYEDr. Agarwal's Health Care Limited
Convert to ideaHealthcare · Healthcare Facilities
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeUp 0.2 this quarter.
Momentum from moving averages, Supertrend and RSI.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
Forensic screen of the latest filings
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹655 Cr | ₹57 Cr | 14.21% | 8.67% | ₹1.65 | 4.5x |
| Q1 FY2027 | ₹614 Cr | ₹55 Cr | 15.00% | 8.96% | ₹1.43 | 4.2x |
| Q4 FY2026 | ₹564 Cr | ₹50 Cr | 15.03% | 8.86% | ₹1.25 | 4.5x |
| Q3 FY2026 | ₹530 Cr | ₹44 Cr | 14.22% | 8.23% | ₹1.07 | 4.1x |
| Q2 FY2026 | ₹499 Cr | ₹36 Cr | 13.69% | 7.32% | ₹0.94 | 3.4x |
| Q1 FY2026 | ₹487 Cr | ₹38 Cr | 13.32% | 7.81% | ₹0.95 | 3.2x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Healthcare Facilities
Compare with peers →Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the treatment of glaucoma and pterygium; doctor consultation services; and diagnostic services for eye disorders along with non-surgical treatments, including retinal laser therapy and dry eye treatment services. It also sells glasses, lenses, contact lenses, and frames; and eye care-related pharmaceutical products. The company was incorporated in 2010 and is based in Chennai, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.